IP Library Granted Patent US 11,434,299
Granted Patent B2
US 11,434,299 · App. 16/472,173 · Granted Sep 6, 2022

Anti-BCMA heavy chain-only antibodies

Inventors: Shelley Force Aldred (Newark, CA); Nathan Trinklein (Newark, CA); Katherine E. Harris (Newark, CA); Kevin Dang (Newark, CA); Wim van Schooten (Newark, CA)
Assignee: TeneoBio, Inc.
C07K16/2878C07K2317/21C07K2317/31C07K2317/565C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,434,299
App. No.
16/472,173
Granted
Sep 6, 2022
Kind
B2
Abstract

Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Claims (20)

1. A heavy chain-only antibody binding to human B-Cell Maturation Antigen (BCMA) comprising a heavy chain variable region comprising:

(a) a CDR1 sequence comprising SEQ ID NO: 1, a CDR2 sequence comprising SEQ ID NO: 5, and a CDR3 sequence comprising SEQ ID NO: 19; or

(b) a CDR1 sequence comprising SEQ ID NO: 2, a CDR2 sequence comprising SEQ ID NO: 54, and a CDR3 sequence comprising SEQ ID NO: 19;

in a human VH framework.

2. The heavy chain-only antibody of claim 1 , further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.

3. The heavy chain-only antibody of claim 1 , which is in a CAR-T format.

4. The heavy chain-only antibody of claim 1 , which is present in a CAR-transduced T-cell.

5. A pharmaceutical composition comprising the heavy chain-only antibody of claim 1 .

6. The heavy chain-only antibody of claim 1 , wherein the heavy chain variable region comprises a CDR1 sequence comprising SEQ ID NO: 1, a CDR2 sequence comprising SEQ ID NO: 5, and a CDR3 sequence comprising SEQ ID NO: 19, in a human VH framework.

7. The heavy chain-only antibody of claim 6 , wherein the heavy chain variable region has at least 95% sequence identity to SEQ ID NO: 20.

8. The heavy chain-only antibody of claim 7 , wherein the heavy chain variable region comprises SEQ ID NO: 20.

9. The heavy chain-only antibody of claim 6 , further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.

10. The heavy chain-only antibody of claim 6 , which is in a CAR-T format.

11. The heavy chain-only antibody of claim 6 , which is present in a CAR-transduced T-cell.

12. The heavy chain-only antibody of claim 1 , wherein the heavy chain variable region comprises a CDR1 sequence comprising SEQ ID NO: 2, a CDR2 sequence comprising SEQ ID NO: 54, and a CDR3 sequence comprising SEQ ID NO: 19, in a human VH framework.

13. The heavy chain-only antibody of claim 12 , wherein the heavy chain variable region has at least 95% sequence identity to SEQ ID NO: 21.

14. The heavy chain-only antibody of claim 13 , wherein the heavy chain variable region comprises SEQ ID NO: 21.

15. The heavy chain-only antibody of claim 12 , further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.

16. The heavy chain-only antibody of claim 12 , which is in a CAR-T format.

17. The heavy chain-only antibody of claim 12 , which is present in a CAR-transduced T-cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2024
From: FORCE ALDRED, SHELLEY; TRINKLEIN, NATHAN; HARRIS, KATHERINE; DANG, KEVIN; VAN SCHOOTEN, WIM
To: TENEOBIO, INC.
Reel/Frame 066499/0890 →
Continuity (2)
Provisional Application 62437588 · Dec 21, 2016
Related Publication 20190352412A1 · Nov 21, 2019
Cited By (3)
US 12,371,505 US 12,495,776 US 12,709,644